Coated nanoparticles for use for modulating electrical polarization of neurons
Inventors
Pottier, Agnès • Levy, Laurent • Meyre, Marie-Edith
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11229705-B2
Publication Date
2022-01-25
Expiration Date
Abstract
The present invention relates to the medical field, in particular to the modulation of electrical polarization of neurons. More specifically the present invention relates to a nanoparticle or nanoparticles' aggregate for use for modulating electrical polarization of neurons in a subject, for example for use in prevention or treatment of a neuronal disease in a subject, typically by modulating electrical polarization of neurons in the subject, wherein i) when the nanoparticle or nanoparticles' aggregate is exposed to a light source, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction, ii) when the nanoparticle or nanoparticles' aggregate is exposed to a magnetic field, the nanoparticle's or nanoparticles' aggregate's material is selected from a material enabling magneto-electric transduction or magneto-thermal transduction, iii) when the nanoparticle or nanoparticles' aggregate's surface is exposed to an ultrasound source, the nanoparticle's or nanoparticles' aggregate's material is a material enabling acousto-electric transduction, and wherein the nanoparticle or nanoparticles' aggregate is either neutrally charged in the absence of any coating or is coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticles' aggregate. It further relates to compositions and kits comprising such nanoparticles and/or nanoparticles' aggregates as well as to uses thereof.
Core Innovation
The invention relates to treating a neuronal disease in a subject by modulating electrical polarization of neurons using administered coated nanoparticles or nanoparticle aggregates. Upon exposure to a light source, a magnetic field, or an ultrasound source, the nanoparticles or nanoparticle aggregates enable transduction that modulates neuronal electrical polarization, and the nanoparticle material is selected to correspond to the transduction type enabled by the applied stimulus.
The nanoparticles or nanoparticle aggregates have a surface that is neutrally charged, either without coating or coated with a hydrophilic agent that confers neutral surface charge. The neutral surface charge is about −10 mV to +10 mV.
The disclosure further specifies that the administered composition comprises at least two distinct nanoparticles and/or nanoparticle aggregates, each consisting of a distinct material enabling a listed transduction mechanism, with the surfaces optionally coated with a hydrophilic agent conferring neutral surface charge. The described material classes include semiconductor material with semiconductor band gap Eg <3.0 eV for opto-electric transduction, plasmonic metals for opto-thermal transduction, lanthanide-doped materials for opto-optical transduction, CoFe2O4@BaTiO3 for magneto-electric transduction, superparamagnetic oxides such as Fe3O4/Fe2O3 for magneto-thermal transduction, and piezoelectric materials such as BaTiO3, SrTiO3, and BN for acousto-electric transduction.
Claims Coverage
The provided independent claims cover a method of treating a neuronal disease by administering a nanoparticle/nanoparticle aggregate composition selected for stimulus-specific transduction and exposing the subject to a corresponding light, magnetic field, or ultrasound source to modulate neuronal electrical polarization. Across the independent claims, the coverage hinges on three core inventive features: stimulus-matched transduction materials, a neutrally charged nanoparticle surface, and at least two distinct nanoparticle types/materials.
Stimulus-matched transduction-enabled nanoparticle materials
Wherein, when the nanoparticle or nanoparticle aggregate is exposed to a light source, the nanoparticle or nanoparticle aggregate material is selected from a material enabling opto-electric transduction, opto-thermal transduction or opto-optical transduction; when exposed to a magnetic field, the nanoparticle or nanoparticle aggregate material is a material enabling magneto-electric transduction or magneto-thermal transduction; and when exposed to an ultrasound source, the nanoparticle or nanoparticle aggregate material is a material enabling acousto-electric transduction.
Neutrally charged nanoparticle surface via uncoated neutral charge or hydrophilic neutral-charge coating
And wherein the nanoparticle or nanoparticle aggregate surface is either neutrally charged in the absence of any coating or coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate, the neutral charge being of about −10 mV to +10 mV.
At least two distinct nanoparticle types enabling distinct transduction mechanisms
Wherein the nanoparticle or nanoparticle aggregate of step a) is at least two distinct nanoparticles and/or nanoparticle aggregates, each nanoparticle or nanoparticle aggregate consisting of a distinct material selected from a material enabling opto-electric transduction, opto-thermal transduction, opto-optical transduction, magneto-electric transduction, magneto-thermal transduction or acousto-electric transduction, and the nanoparticle or nanoparticle aggregate surface being optionally coated with a hydrophilic agent conferring a neutral surface charge to the nanoparticle or nanoparticle aggregate.
Administering with pharmaceutically acceptable support
Administering a composition to the subject, the composition comprising nanoparticles and/or nanoparticle aggregates and a pharmaceutically acceptable support.
The independent claims require administering nanoparticle/nanoparticle aggregate compositions whose materials enable opto-electric, opto-thermal, opto-optical, magneto-electric, magneto-thermal, or acousto-electric transduction depending on the applied stimulus; nanoparticle surface neutrality about −10 mV to +10 mV via either no coating or a hydrophilic agent conferring neutral charge; and at least two distinct nanoparticle types/materials enabling distinct transduction mechanisms, with one independent claim also specifying inclusion of a pharmaceutically acceptable support.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?